Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$2.90
-11.9%
$3.48
$2.55
$6.59
$31.28M1.6364,660 shs118,990 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.40
-4.2%
$0.53
$0.37
$1.53
$34.66M1564,141 shs710,082 shs
Pluri Inc. stock logo
PLUR
Pluri
$4.55
+1.1%
$4.59
$3.33
$7.13
$35.64M0.7715,937 shs8,534 shs
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$1.01
-2.9%
$0.94
$0.58
$41.85
$8.78M0.065.16 million shs515,890 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-11.85%-16.67%-19.22%-28.40%-53.75%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-4.16%-6.68%-27.90%-43.83%-63.21%
Pluri Inc. stock logo
PLUR
Pluri
-0.22%-6.57%-18.17%+2.25%-24.42%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
-2.88%+11.70%+8.10%-12.17%+100,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2.843 of 5 stars
3.54.00.00.03.30.01.3
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
1.5751 of 5 stars
3.44.00.00.01.60.00.0
Pluri Inc. stock logo
PLUR
Pluri
0.2595 of 5 stars
0.03.00.00.01.90.80.0
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
3.00
Buy$25.00762.07% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.75
Moderate Buy$4.33980.63% Upside
Pluri Inc. stock logo
PLUR
Pluri
0.00
N/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
3.00
Buy$5.00395.05% Upside

Current Analyst Ratings Breakdown

Latest SLXN, ONCY, PLUR, and LTRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/16/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/2/2025
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
3/20/2025
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $5.00
3/10/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $3.00
3/10/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/10/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$3.76 per shareN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.27 per shareN/A
Pluri Inc. stock logo
PLUR
Pluri
$1.03M34.47N/AN/A($0.42) per share-10.83
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/A$0.69 per share1.46($6.63) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$15.96M-$1.84N/AN/AN/AN/A-56.91%-51.17%8/14/2025 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$20.56M-$0.29N/AN/AN/AN/A-141.15%-84.73%7/30/2025 (Estimated)
Pluri Inc. stock logo
PLUR
Pluri
-$20.89M-$5.53N/AN/A-3,551.49%-2,778.13%-83.61%N/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
$260KN/A0.00N/AN/AN/A-249.43%6/17/2025 (Estimated)

Latest SLXN, ONCY, PLUR, and LTRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.49-$0.42+$0.07-$0.42N/AN/A
5/14/2025Q1 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.09-$0.06+$0.03-$0.06N/AN/A
5/13/2025Q3 2025
Pluri Inc. stock logo
PLUR
Pluri
N/A-$0.94N/A-$0.94N/A$0.43 million
5/13/2025N/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A-$0.26N/A-$0.26N/AN/A
3/27/2025Q4 2024
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.51-$0.54-$0.03-$0.54N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
N/AN/AN/AN/AN/A
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
8.31
8.31
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
2.99
2.99
Pluri Inc. stock logo
PLUR
Pluri
4.44
5.04
5.04
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A
0.85
0.85

Institutional Ownership

CompanyInstitutional Ownership
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
Pluri Inc. stock logo
PLUR
Pluri
16.59%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
10.95%

Insider Ownership

CompanyInsider Ownership
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
7.31%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
Pluri Inc. stock logo
PLUR
Pluri
10.20%
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
2010.79 million10.00 millionOptionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3086.42 million85.42 millionNot Optionable
Pluri Inc. stock logo
PLUR
Pluri
1507.83 million6.28 millionOptionable
Silexion Therapeutics Corp stock logo
SLXN
Silexion Therapeutics
N/A8.69 million1.07 millionN/A

Recent News About These Companies

Silexion Therapeutics Corporation Registered Shs
Silexion Therapeutics enters collaboration with Catalent
Silexion Therapeutics announces expanded development plan for SIL204
Silexion announces completion of expanded development plan for SIL204
Silexion Therapeutics price target lowered to $5 from $9 at Maxim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$2.90 -0.39 (-11.85%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.05 +0.15 (+5.21%)
As of 05/27/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$0.40 -0.02 (-4.16%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.40 -0.01 (-1.25%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Pluri stock logo

Pluri NASDAQ:PLUR

$4.55 +0.05 (+1.11%)
Closing price 05/27/2025 03:55 PM Eastern
Extended Trading
$4.50 -0.05 (-1.10%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Silexion Therapeutics stock logo

Silexion Therapeutics NASDAQ:SLXN

$1.01 -0.03 (-2.88%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.96 -0.05 (-4.55%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.